CL2025001156A1 - Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer. - Google Patents

Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer.

Info

Publication number
CL2025001156A1
CL2025001156A1 CL2025001156A CL2025001156A CL2025001156A1 CL 2025001156 A1 CL2025001156 A1 CL 2025001156A1 CL 2025001156 A CL2025001156 A CL 2025001156A CL 2025001156 A CL2025001156 A CL 2025001156A CL 2025001156 A1 CL2025001156 A1 CL 2025001156A1
Authority
CL
Chile
Prior art keywords
cldn4
bispecific antibody
signaling inhibitor
treatment
combination
Prior art date
Application number
CL2025001156A
Other languages
English (en)
Spanish (es)
Inventor
Sato Masahito
HIROUCHI Keita
Kikuchi Aya
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CL2025001156A1 publication Critical patent/CL2025001156A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2025001156A 2022-10-19 2025-04-16 Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer. CL2025001156A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022167362 2022-10-19

Publications (1)

Publication Number Publication Date
CL2025001156A1 true CL2025001156A1 (es) 2025-05-23

Family

ID=90737914

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025001156A CL2025001156A1 (es) 2022-10-19 2025-04-16 Uso del anticuerpo biespecífico anti-cldn4/anti-cd137 combinado con inhibidor de señales de pd-1 para tratar cáncer.

Country Status (10)

Country Link
EP (1) EP4606384A1 (cg-RX-API-DMAC7.html)
JP (1) JP7730432B2 (cg-RX-API-DMAC7.html)
KR (1) KR20250089513A (cg-RX-API-DMAC7.html)
CN (1) CN119997975A (cg-RX-API-DMAC7.html)
AU (1) AU2023365438A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025001156A1 (cg-RX-API-DMAC7.html)
IL (1) IL319946A (cg-RX-API-DMAC7.html)
MX (1) MX2025004457A (cg-RX-API-DMAC7.html)
TW (1) TW202426503A (cg-RX-API-DMAC7.html)
WO (1) WO2024085166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026042803A1 (ja) * 2024-08-21 2026-02-26 アステラス製薬株式会社 がん治療におけるプラチナ系薬剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
PL2346994T3 (pl) 2008-09-30 2022-04-19 Ablexis, Llc Myszy knock-in do wytwarzania chimerycznych przeciwciał
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2707723B1 (en) 2011-05-12 2016-02-10 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
BR112015007184A2 (pt) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
MX380176B (es) * 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
EP3064507A1 (en) * 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
BR112018071612A2 (pt) * 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
PH12022552323A1 (en) * 2020-03-31 2023-12-04 Chugai Pharmaceutical Co Ltd Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
CN116133684B (zh) 2020-05-27 2025-07-18 阿里亚利斯治疗公司 抗人nr1抗体衍生物
IL307744A (en) * 2021-04-22 2023-12-01 Astellas Pharma Inc Anti-CLDN4/anti-CD137 bispecific antibody

Also Published As

Publication number Publication date
MX2025004457A (es) 2025-05-02
AU2023365438A1 (en) 2025-04-17
IL319946A (en) 2025-05-01
JPWO2024085166A1 (cg-RX-API-DMAC7.html) 2024-04-25
TW202426503A (zh) 2024-07-01
WO2024085166A1 (ja) 2024-04-25
CN119997975A (zh) 2025-05-13
JP7730432B2 (ja) 2025-08-27
EP4606384A1 (en) 2025-08-27
KR20250089513A (ko) 2025-06-18

Similar Documents

Publication Publication Date Title
BR112022004913A2 (pt) Derivado de camptotecina e conjugado do mesmo
MX2019014761A (es) Manejo de toxicidad para actividad antitumoral de cars.
CL2024000318A1 (es) Compuestos de pirazolopiridinona
MX368507B (es) Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-ctla-4 en la manufactura de un medicamento para el tratamiento de cáncer.
ECSP20082338A (es) Receptores del factor de crecimiento quimérico
PH12014500965A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
AR128108A1 (es) Indoles, indazoles y análogos relacionados para inhibir yap / taz-tead
ECSP20020949A (es) Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
JOP20230261A1 (ar) جسم مضاد ثنائي النوعية لـ cldn4/cd137
EA202091203A1 (ru) Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b
CL2024002763A1 (es) Dosificación no lineal de mirdametinib
MX2024012620A (es) Regimenes de dosificacion para agentes anti-cd19 y usos de los mismos
MX2025009913A (es) Anticuerpos anti-cd3 y metodos para su uso
MX2018014576A (es) Nanopartículas para el suministro de fármaco y tratamientos para el cáncer resistente a fármacos.
AR066690A1 (es) Agentes terapeuticos para canceres resistentes a agentes quimioterapeuticos que incluyen como ingrediente activo un anticuerpo que reconoce hla de clase i y sus usos
MX2023011931A (es) Materiales y métodos para mejorar la ingenieria de células t de memoria similares a células madre.
CL2023002484A1 (es) Conjugados de arni y usos de los mismos
DOP2023000216A (es) Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
AR128110A1 (es) Tetrahidropirazolopirimidinas y análogos relacionados para la inhibición de yap / taz tead
CO2025004806A2 (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, métodos terapéuticos y usos de los mismos
MX2024012392A (es) Terapia combinada para el tratamiento del cancer
MX2022009041A (es) Metodos de dosificacion y tratamiento de linfoma folicular y linfoma de zona marginal en terapia celular adoptiva.
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
MX2021008303A (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa.
MX2025004457A (es) Uso del anticuerpo biespecifico anti-cldn4/anti-cd137 combinado con un inhibidor de las se?ales de la pd-1 para el tratamiento de cancer